Utilizing a novel tandem oral dosing strategy to enhance exposure of low-solubility drug candidates in a preclinical setting

Journal of Pharmaceutical Sciences

Volumn 99, Issue 7, 2010, Pages 3132-3140

  Chiang, P O Chang ^a   South, Sarah A ^a   Foster, Kimberly A ^a   Scott Daniels, J ^a   Wene, Steve P ^a   Albin, Lesley A ^a   Thompson, David C ^a  

^a PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United States)

Author keywords

Efficacy; Exposure; Gastrointestinal; In vivo; Oral; Resources; Safety; Tandem

Indexed keywords

MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; PHOSPHODIESTERASE INHIBITOR;

ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DOSAGE SCHEDULE COMPARISON; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG DOSE COMPARISON; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG EXPOSURE; DRUG FORMULATION; DRUG INFUSION; DRUG SAFETY; DRUG SOLUBILITY; IC 50; IN VIVO STUDY; MALE; NONHUMAN; RAT;

EID: 77953306622     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.22092     Document Type: Article

References (33)

1. Bittner B, Mountfield RJ. 2002. Intravenous administration of poorly soluble new drug entities in early drug discovery: The potential impact of formulation on pharmacokinetic parameters. Current Opinion in Drug Disc. & Dev. 5:59-71. (Pubitemid 34453243)
2. Barrett ER. 2004. Nanosuspensions in drug delivery. Nature Reviews Drug Discovery. 3:785-796.
3. Dove A. 1999. Drug screening-beyond the bottleneck. Nat Biotechnol. 17:859-864.
4. Brazeau GA, Fung HL. 1990. Effect of organic cosolvent-induced skeletal muscle damage on the bioavailability of intramuscular [14C]diazepam. J Pharm. Sci. 79:773-777.
5. Korttila K, Sothman A, Andersson P. 1976. Polyethylene glycol as a solvent for diazepam: bioavailability and clinical effects after intramuscular administration, comparison of oral, intramuscular and rectal administration, and precipitation from intravenous solutions. Acta Pharmacol Toxicol (Copenh) 39:104-117.
6. Langer RS, Peppas NA. 1981. Present and future applications of biomaterials in controlled drug delivery systems. Biomaterials 2:201-214.
7. Peppas NA, Langer R. 1994. New challenges in biomaterials. Science 263:1715-1720.
8. Kocbek P, Baumgartner S, Kristl J. 2006. Preparation and evaluation of nanosuspensions for enhancing the dissolution of poorly soluble drugs. Int. J. Pharm. 312:179-186.
9. Rabinow BE. 2004. Nanosuspensions in drug delivery. Nat. Rev. Drug Discov. 3:785-796.
10. Chiang P, Wahlstrom J, Selbo J, Zhou S, Wene S, Albin L, Warren C, Smith M, Roberds S, Ghosh S, Zhang L, Pretzer DK. 2007. 1,3 Dicyclohexyl Urea Nanosuspension for Intravenous Steady-State Delivery in Rat. J. Exp. Nano. 2:239-250.
11. Grau MJ, Kayser O, Muller RH. 2000. Nanosuspensions of poorly soluble drugs reproducibility of small scale production. Int J Pharm 196:155-159. (Pubitemid 30105733)
12. Munakata A, Iwane S, Todate M, Nakaji S, Sugawar K. 1995. Effects of Dietary Fiber on Gastrointestinal Transit Time, Fecal Properties and Fat Absorption in Rats. Tohoku J. Exp. Med. 176:227-238.
13. Tomlin J, Brown N, Ellis A, Carlsson A, Bogentoft C, Read NW. 1993. The effect of liquid fiber on gastric emptying in the rat and humans and the distribution of smallintestinal contents in the rat. Gut. 34:1177-1181. (Pubitemid 23274535)
14. Wang SC, Lu K, Chen S, Young TK. 2001. Gastric Emptying and Intestinal Transit of Liquid and Solid Markers in Rats with Chronic Uremia. Chinese Journal of Physiology 44:81-87.
15. Davies B, Morris T. 1993. Physiological parameters in laboratory animals and humans. Pharm. Res. 10:1093-1095.
16. Oberle RL, Chen TS, Lloyd C, Barnett J, Owyang C, Meyer J, Amidon GL. 1990. The influence of interdigestive migrating myoelectric complex on the gastric emptying of liquids. Gastroenterology. 99:1275-1282. (Pubitemid 20381860)
17. DeSesso JM, Jacobson CF. 2001. Anatomical and Physiological parameters affecting gastrointestinal absorption in human and rats. Food and Chemical Tox. 39:209-228.
18. Smith SE. 1987. Physiology of the gastrointestinal tract in relation to drug absorption. Int. Pharmacy J. 1:101-104.
19. Kararli TT. 1995. Comparsion of the gastrointestinal anatomy, physiology, and biochemistry of humans and commonly used laboratory animals. BioPharmaceutics and Drug Disposition. 16:351-380.
20. Willmann S, Schmitt W, Keldenich J, Dressman JB. 2003. A Physiologic Model for Simulating Gastrointestinal Flow and Drug Absorption in Rats. Pharm. Res. 20:1766-1771.
21. Bollard ME, Stanley EG, Wang Y, Lindon JC, Nicholson JK, Holmes E. 2005. Physiological variation in laboratory animals and humans. In: Robertson DG, Lindon JC, Nicholson JK, Holmes E, editors. Metabonomics in toxicity assessment. Boca Raton, US: CRC Press.
22. Hitti E, Iakovleva T, Brook M, Deppenmeier S, Gruber AD, Radzioch D, Clark AR, Blackshear PJ, Kotlyarov A, Gaestel M. 2006. Mitogen-Activated Protein Kinase-Activated Protein Kinase 2 Regulates Tumor Necrosis Factor mRNA Stability and Translation Mainly by Altering Tristetraprolin Expression, Stability, and Binding to Adenine/Uridine-Rich Element. Mol Cell Biol 26:2399-2407. (Pubitemid 43346938)
23. Dean JL, Sully G, Clark AR, Saklatvala J. 2004. The involvement of AU-rich element-binding proteins in p38 mitogen-activated protein kinase pathway-mediated mRNA stabilisation. Cell Signal 16:1113-1121.
24. Fechir M, Linker K, Pautz A, Hubrich T, Forstermann U, Rodriguez-Pascual F, Kleinert, H. 2005. Tristetraprolin regulates the expression of the human inducible nitric-oxide synthase gene. Mol. Pharmacol 67:2148-2161. (Pubitemid 41007794)
25. Tietz AB, Malo A, Diebold J, Kotlyarov A, Herbst A, Kolligs FT, Brandt-Nedelev B, Halangk W, Gaestel M, Göke B, Schäfer C. 2006. Gene Deletion of MK2 Inhibits TNF-α and IL-6 and Protects Against Cerulein-induced pancreatitis. Am J Physiol Gastrointest Liver Physiol 290:G1298-G1306.
26. Young DA, Hegen M, Ma HLM, Whitters MJ, Albert LM, Lowe L, Senices M, Wu PW, Sibley B, Leathurby Y, Brown TP, Nickerson-Nutter C, Keith KC Jr, Collins M. 2007. Blockade of the interleukin-21/interleukin-21 receptor pathway ameliorates disease in animal models of rheumatoid arthritis. Arthritis Rheum 56:1152-1163. (Pubitemid 46608640)
27. Almholt DLC, Loechel F, Nielsen SJ, Krog-Jensen K, Terry R, Bjørn SP, Pedersen HC, Præstegaard M, Møller S, Heide M, Pagliaro L, Mason AJ, Butcher S, Dahl SW. 2004. Nuclear Export Inhibitors and Kinase Inhibitors Identified Using a MAPK-Activated Protein Kinase 2 Redistribution® Screen. Assay and Drug Development Tech 2:7-20.
28. Zhang T, Kruys V, Huez G, Gueydan C. 2002. AU-rich element-mediated translational control: complexity and multiple activities of trans-activating factors. Biochem. Soc. Trans 30:952-958.
29. Wilson GM, Sutphen K, Moutafis M, Sinha S, Brewer G. 2001. Session 12: Post-transcriptional regulation of cytokine expression. Immunology 104:S1. 45-46.
30. Comite GD, Marinosci A, Dimatteo P, Manfredi A, Roverequerini A, Ldissera E, Aiello P, Corti A, Sabbadini MA. 2006. Neuroendocrine Modulation Induced by Selective Blockade of TNF-α in Rheumatoid Arthritis. Annals of the New York Academy of Sciences (Basic and Clinical Aspects of Neuroendocrine Immunology and Rheumatic Diseases), 1069:428-437. (Pubitemid 43989886)
31. Masood A, Nadeem A, Mustafa SJ, O'Donnell JM. 2008. Reversal of, Oxidative Stress-Induced, Anxiety by, Inhibition of, Phosphodiesterase-2 in, Mice. JPET. 326:369-379.
32. Suvarna NU, O'Donnell JM. 2002. Hydrolysis of N-methyl-D-aspartate receptorstimulated cAMP and cGMP by PDE4 and PDE2 phosphodiesterases in primary neuronal cultures of rat cerebral cortex and hippocampus. J Pharmacol. Exp. Ther. 302: 249-256.
33. Kwon Y. 2001. Handbook of Essential Pharmacokinetics, Pharmacodynamics, and Drug Metabolism for Industrial Scientists. New York, NY, USA: Kluwer Academic/ plenum publishers.